What Seniors, Providers, and the Industry Need to Know Now
Senior Wellness
THC
The Evolution of Cannabis in 2026
A New Chapter in Cannabis Policy
What Seniors, Providers, and the Industry Need to Know Now
by Sara Figueroa, contributing writer
The landscape of cannabis in the United States is undergoing one of the most important shifts in decades. Once dismissed as having“ no accepted medical use,” cannabis is now increasingly recognized for its therapeutic potential— and 2026 represents a major turning point.
Recent federal actions have removed barriers to research, clarified protections for healthcare providers, and opened the door to new care models. The Medical Marijuana and Cannabidiol Research Expansion Act, signed by President Biden in December 2022, affirmed that medical professionals can legally recommend cannabis as a treatment and strengthened their right to discuss it openly with patients.
On April 22, 2026, FDA-approved products containing cannabis, as well as cannabis that is legal via a state-issued medical marijuana license, were placed into Schedule III. While this is a meaningful development— its medical value is formally acknowledged at the federal level— cannabis remains tightly regulated and not fully legalized nationwide.
Why This Matters for Older Adults
For America’ s aging population, these changes could be especially meaningful.
Many adults over 65 live with chronic conditions such as arthritis, chronic pain, anxiety, or sleep disorders. At the same time, they often manage multiple prescriptions daily, sometimes at significant risk. In a recent study published in the journal Palliative Care and Social Practice, an analysis of 1,269 patients over age 65 showed that nearly 80 % were prescribed at least one potentially inappropriate medication six months before death.
Every day, 750 people over age 65 are hospitalized due to complications from one or more FDA-approved medications.
We are seeing study after study emerge showing that people can significantly reduce their use of many types of pharmaceutical drugs after experimenting with medical cannabis, often reporting increased function, better quality of life, and fewer unpleasant side effects.
Medicare’ s New CBD Pilot Program
As the savvy consumer of medical cannabis news that you are, you may have already seen headlines about a newly authorized Centers for Medicare & Medicaid Services( CMS) pilot program where medical cannabis products would be covered, up to $ 500 per year. However, this pilot program will be available only to a select few providers and even fewer patients.
Under the CMS, the Center for Medicare & Medicaid Innovation( CMMI) is an agency where various payment and service models for health care are tested out on healthcare providers and their patients. These healthcare providers— physician groups, hospitals, mental health facilities, and rehabilitation centers that handle a minimum of 5,000 Medicare patients per year and meet other rigorous requirements— are called Accountable Care Organizations( ACO). The goal is to provide financial incentives for providers who agree to the pilot program’ s guidelines.
Ultimately, the role of the CMMI is to identify the most costeffective way to deliver the highest-quality health care. As an avenue for legalization, advocates for medical cannabis can use the potential here of cannabis-supported“ deprescribing” of unnecessary drugs by providers as an argument for the expansion of a federal medical cannabis program. There are still many legislative and bureaucratic hurdles to cross before this can be implemented nationwide.
26 JUNE 2026